Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q4 2020 Results - Earnings Call Transcript
03:24pm, Friday, 26'th Feb 2021
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q4 2020 Results - Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Surpasses Q4 Earnings and Revenue Estimates
08:21am, Friday, 26'th Feb 2021
Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Amneal Receives Approval for Generic Version of Ortho Evra®
06:02am, Friday, 26'th Feb 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval
Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
06:00am, Friday, 26'th Feb 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremel
Why Amneal Pharmaceuticals (AMRX) Might Surprise This Earnings Season
09:08am, Thursday, 25'th Feb 2021
Amneal Pharmaceuticals (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AMRX or CORT: Which Is the Better Value Stock Right Now?
12:27pm, Wednesday, 10'th Feb 2021
AMRX vs. CORT: Which Stock Is the Better Value Option?
Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021
08:00am, Thursday, 04'th Feb 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February
AMRX or PCRX: Which Is the Better Value Stock Right Now?
12:47pm, Friday, 15'th Jan 2021
AMRX vs. PCRX: Which Stock Is the Better Value Option?
Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals
06:00am, Tuesday, 12'th Jan 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement
Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference
09:23am, Tuesday, 05'th Jan 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present at
Amneal Analyst: Pharma Well-Positioned Ahead Of 2021 Generic Launches
02:45pm, Monday, 14'th Dec 2020
As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
08:35am, Wednesday, 11'th Nov 2020
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S.
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript
05:28pm, Friday, 06'th Nov 2020
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript
Recap: Amneal Pharmaceuticals Q3 Earnings
07:53am, Friday, 06'th Nov 2020
Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.
Amneal Reports Third Quarter 2020 Financial Results
06:00am, Friday, 06'th Nov 2020
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered anothe
